Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy’s Pounces On US Ciprodex Generic As Endo Stumbles

Follows Expiry Of Key Ciprodex Patents

Executive Summary

Dr Reddy’s Laboratories has leapfrogged Endo by launching a generic version of of Bayer/Alcon’s Ciprodex (ciprofloxacin/dexamethasone) 0.3%/0.1% otic suspension, as the US firm was stung with a major rejection by the US FDA.

You may also be interested in...



Endo Aims To Stabilize Generics Unit In 2021

Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.

Endo Wields The Axe Again As It Eyes $95m Annual Savings

Hundreds more jobs are to go at Endo under further cost-cutting measures, including the closure of multiple sites serving the US-based player’s Generics business. Management discussed the issue on Endo’s third-quarter earnings call.

Updated: Reddy's Follows Endo On US Kuvan Launch

Under the terms of a patent-litigation settlement from April 2017, Endo’s Par subsidiary has launched the first US generic versions of BioMarin’s Kuvan (sapropterin) tablet and powder formulations. Rival ANDA sponsor Dr Reddy’s has followed suit on the tablet formulation.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel